BioTech

High Hopes on Ariad (ARIA, MRK)

BioTech Investor - BioTech Stock News - 10 March 2010 - 4:02pm
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is seeing elevated trading today after a presentation and ahead of earnings. The difference here is that Ariad’s increased trading is in both the stock and in the bonds. Joe Kunkle of OptionsHawk.com noted, “implied volatility is 10% higher to 87.8% as shares gain 2.7%, 4,140 calls trading, [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

More Drug and BioHealth Dividends (MRX, WCRX, AMGN, MRK, PFE, PPH, BBH)

BioTech Investor - BioTech Stock News - 10 March 2010 - 11:08am
Medicis (NYSE: MRX), a specialty pharmaceutical company in treatments of dermatological and aesthetic conditions, has the talk going again about dividends in the drug and biotech sector.  The company declared a quarter-end cash quarterly dividend of $0.06 payable on April 30, 2010 for holders of record at the close of business on April 1, 2010.  [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

The Facet Biotech Buyout Saga (FACT, BIIB, ABT, PDLI)

BioTech Investor - BioTech Stock News - 10 March 2010 - 9:30am
Facet Biotech Corporation (NASDAQ: FACT) is a buyout saga that seemed as though it would never end in 2009.  The company is now finally being acquired, but not by Biogen Idec (NASDAQ: BIIB).  Abbott Laboratories (NYSE: ABT) announced last night that it entered into a definitive agreement for $27.00 per share in a cash buyout.  [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

EDAP TMS, Back on the Map (EDAP)

BioTech Investor - BioTech Stock News - 9 March 2010 - 2:20pm
EDAP TMS SA (NASDAQ: EDAP) is a French company which makes medical devices for the treatment of urological diseases and the company’s stock is soaring after the company was granted marketing approval of its newly designed, high-end Sonolith I-Sys lithotripsy device by the Japanese Administration.  Because this market is still under-served, we wanted to look [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Amylin & Friends Brace for Diabetes Review (AMLN, LLY, ALKS)

BioTech Investor - BioTech Stock News - 8 March 2010 - 3:44pm
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) has a big event on deck this week.  This Friday, March 12, is its Prescription Drug User Fee Act (PDUFA) action date for an FDA panel to issue a recommendation on Byetta as the the first once a week treatment for Type II diabetes.  The date had been moved due [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

The Changing Landscape of Biotech Valuations (ACOR, CBST, MNKD, INCY, SGEN, ITMN, IPXL, MRX, SVNT, VPHM)

BioTech Investor - BioTech Stock News - 6 March 2010 - 4:12pm
The biotech and biohealth universe is changing in size.  In 2008 and 2009, partly due to mergers and partly due to market valuations, there had become a surprisingly small number of biotech stocks which had market capitalization rates of more than $1 billion.  At one point there were only about 10 or 11 in our [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

When Biotech Layoffs Come (XNPT)

BioTech Investor - BioTech Stock News - 5 March 2010 - 3:34pm
When conglomerates and consumer products lay off workers and employees, shareholders generally cheer the company for saving money and cutting costs by figuring out productivity measures that milk more output per employee.  That leaves more income and ultimately brings more dividends down the road.  But biotech firms are far from being thought of in the [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Winning from Boosting Good Cholesterol (RVXCF, RVX, PFE, AZN, MRK)

BioTech Investor - BioTech Stock News - 5 March 2010 - 12:13pm
BioHealthInvestor usually sticks to US companies or at least sticks to ADRs for investors.  But sometimes there is a much larger bit of data either north of the border or in Europe.  There is a company called  Resverlogix Corp. which trades in Canada under the ticker ‘RVX’ and the stock also trades in the US [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Talking Biotech ETFs: iShares Nasdaq Biochnology to $100 (IBB, OSIP, MDVN)

BioTech Investor - BioTech Stock News - 3 March 2010 - 4:49pm
Today’s price moves in the biotech sector are quite different from what we saw earlier this week.  A hostile merger via tender from Astellas for OSI Pharmaceuticals Inc. (NASDAQ: OSIP) got everyone up in arms this week.  So much that other investors were going back over buyout candidate notes.  We also gave a list of [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Biotech Implosion: Medivation, Alzheimer’s Beats Drug (MDVN, PFE)

BioTech Investor - BioTech Stock News - 3 March 2010 - 9:36am
Medivation, Inc. (NASDAQ: MDVN) is the next biotech implosion.  The company’s highly awaited Phase III study on its Alzheimer drug called Dimebon did not meet expectations. It failed to meet primary and secondary endpoints. The problem is that this was hitting 52-week highs yesterday. The company did note that a separate Phase 3 safety study demonstrated [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

More Biotech Buyout or M&A Targets (OSIP, VRTX, AUXL, ITMN, HGSI, CELG, DNDN, ENZN, FACT, PBE, XBI)

BioTech Investor - BioTech Stock News - 1 March 2010 - 2:06pm
After today’s hostile Astellas offer for OSI Pharmaceuticals (NASDAQ: OSIP), we have investors and traders alike looking for ‘the next takeover target’ in biotech.  Buy now you know that there are many pitfalls in simply looking for biotech stocks to buy because they will be taken over.  We have taken a look through our own [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Hostile Mergers Back in Biotech (OSIP)

BioTech Investor - BioTech Stock News - 1 March 2010 - 9:20am
Mergers are back in biotech…. Astellas Pharma Inc., a global pharmaceutical company in Japan, announced that it will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals (NASDAQ: OSIP).  The direct tender is nothing short of a hostile merger after Astellas said that OSI has refused to discuss terms. The [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Generic Drug Wars… Is Dr. Reddy’s The Answer? (RDY, TEVA, GSK)

BioTech Investor - BioTech Stock News - 28 February 2010 - 3:34pm
Generic drugs are just one of the many combined issues that are coming front and center in the world of healthcare reform.   Frankly this is not a new notion.  Not all.  This weekend came a feature in Barron’s “Asian Trader: Pill Maker That’s Set To Pop” calling Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) of India [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

InterMune Volatility Compression (ITMN)

BioTech Investor - BioTech Stock News - 22 February 2010 - 1:25pm
InterMune Inc. (NASDAQ: ITMN) has shown some very interesting options trading, and the trading looks to be a bet against all that huge volatility we have seen. Joe Kunkle of OptionsHawk.com noted: ITMN with a 2,000X4,000X2,000 contract butterfly call spreads at the March $25/$30/$35 strikes.  This trade bets on volatility to collapse, which will happen after the [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Two key Analyst Call in BioHealth Space (DNDN, HGSI)

BioTech Investor - BioTech Stock News - 22 February 2010 - 9:25am
We have seen two very key biotech analyst calls this morning, and shares of both are responding.  Dendreon Corp. (NASDAQ: DNDN) and Human Genome Sciences (NASDAQ: HGSI) were both given positive brokerage initiations this morning. Dendreon Corp. (NASDAQ: DNDN) is seeing gains this morning after the stock was started as “Overweight” and $46 target at JPMorgan.  [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Buyout Rumors Resurface in Biotech, Maybe (DNDN, MYGN)

BioTech Investor - BioTech Stock News - 19 February 2010 - 4:49pm
Sometimes it is the action seen in stock options gets traders moving more than the action in the stock.  With more commentators on CNBC and other media outlets talking about ‘elevated options trading seen in…’ it gets even more on alert.  From our best read today, that seems to be the case in Dendreon Corp. [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Rigel Attacks Rheumatoid Arthritis with AstraZeneca (RIGL, AZN)

BioTech Investor - BioTech Stock News - 16 February 2010 - 9:20am
Rigel Pharmaceuticals (NASDAQ: RIGL) may be the biotech winner this Tuesday.  The company has signed a pact with AstraZeneca (NYSE: AZN) which could ultimately bring in about $1.25 billion if all targets are met.  This pact is a licensing agreement for Rigel’s rheumatoid arthritis drug R788 or fostamatinib disodium. Rigel said last year that its R788 [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Dividends Coming In Biotech & Pharma? (WCRX, AMGN, MRK, PFE, PPH, BBH)

BioTech Investor - BioTech Stock News - 11 February 2010 - 1:36pm
Many investors have been focusing on the number of dividend raises we have so far seen since the end of December.  It is the perfect vote of confidence issued by a company, much more so than a share buyback plan.  The dividend means “we will be able to this rate over and over” for investors.  [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

Cell Therapeutics Facing Tougher FDA (CTIC)

BioTech Investor - BioTech Stock News - 8 February 2010 - 10:47am
Cell Therapeutics, Inc. (NASDAQ: CTIC) is getting clipped on Pixantrone this morning.  The company was told by the FDA that there is limited clinical data on its proposed cancer drug, and that there were higher side effects and higher death incidents.  Unfortunately, this comes ahead of a panel review date that is set for Wednesday, [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

New Restless Leg Syndrome Review for XenoPort (XNPT, GSK)

BioTech Investor - BioTech Stock News - 6 February 2010 - 12:46pm
XenoPort, Inc. (NASDAQ: XNPT) has a big day coming for its GSK1838262/XP13512 (gabapentin enacarbil) next week.  The company has a date of February 9 for an FDA Prescription Drug User Fee Act (PDUFA) decision on its Horizant. This is the dated  goal for the company’s New Drug Application for Horizant for the treatment of moderate-to-severe [...]

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Categories: BioTech

WPS Video Board

Most played videos

Most downloaded

Top videos

Latest image

QASP testing resistance!

Random video

Latest videos

We allll pick stocks. Trade quick DD and tell everybody whats getting sexy tomorrow.

Syndicate content